MARIPOSA - Combination of Amivantamab & Lazertinib for Common EGFR Mutations in NSCLC

Drs. Rahul & Rohit Gosain dived deep into the evolving landscape of metastatic non-small cell lung cancer (NSCLC) with mutated EGFR. Joined by esteemed medical oncology colleagues Drs. Susan Scott, Helena Yu, Estela Rodriguez, and Joshua Sabari, they discussed the latest advancements in treatment options, including Osimertinib, Osimertinib with chemotherapy, and the promising combination of Amivantamab and Lazertinib. Key topics covered include: • The historical context of EGFR-targeted therapies and the introduction of new combination regimens. • Insights from the MARIPOSA trial, focusing on the efficacy and mechanisms of action of Amivantamab and Lazertinib. • The importance of CNS disease management in patients with EGFR mutations and how the MARIPOSA study addresses this. • Proactive management strategies to mitigate side effects associated with these treatments, including cutaneous toxicity and infusion-related reactions. • Clinical pearls for managing side effects and making informed treatment decisions based on patient-specific factors. Follow us on social media: •⁠ ⁠X/Twitter:   / oncbrothers   •⁠ ⁠Instagram:   / oncbrothers   •⁠ Website: https://oncbrothers.com/ Join us for an informative discussion that highlights the importance of personalized treatment approaches in improving patient outcomes and quality of life in metastatic NSCLC. Don't forget to like, subscribe, and share your thoughts in the comments!